21 Aug 2026 , 12:37 PM
The Symbiotec Pharmalab IPO GMP has strengthened sharply ahead of the public issue, with the latest grey market premium rising to ₹320 per share on August 21, 2026.
With the IPO’s upper price band fixed at ₹988 per share, the latest GMP indicates an estimated listing price of ₹1,308 per share, representing a potential premium of 32.39% over the issue price.
The ₹1,757 crore Symbiotec Pharmalab IPO will open for subscription on August 24, 2026, and close on August 27. The issue comprises a fresh issue of ₹150 crore and an offer for sale (OFS) of ₹1,607 crore.
The latest Symbiotec Pharmalab IPO GMP stood at ₹320 per share as of August 21, 2026, according to the available grey market data.
At the upper IPO price of ₹988, the current GMP suggests an estimated listing price of ₹1,308 per share.
This translates into a potential listing premium of 32.39%.
| Particulars | Details |
|---|---|
| IPO Price Band | ₹938–₹988 |
| Upper Price Band | ₹988 |
| Latest GMP | ₹320 |
| Estimated Listing Price | ₹1,308 |
| Estimated Listing Premium | 32.39% |
| Lot Size | 15 Shares |
| Minimum Investment | ₹14,820 |
| IPO Size | ₹1,757 crore |
GMP is an unofficial indicator and does not guarantee the actual listing price.
The grey market premium for Symbiotec Pharmalab has increased significantly over the past three days.
The GMP stood at ₹220 on August 19, before rising to ₹300 on August 20. It increased further to ₹320 on August 21.
| GMP Date | IPO Price | GMP | Estimated Listing Price | Estimated Premium |
|---|---|---|---|---|
| August 21, 2026 | ₹988 | ₹320 | ₹1,308 | 32.39% |
| August 20, 2026 | ₹988 | ₹300 | ₹1,288 | 30.36% |
| August 19, 2026 | ₹988 | ₹220 | ₹1,208 | 22.27% |
The GMP has therefore increased by ₹100 in two days, while the estimated listing premium has climbed from 22.27% to 32.39%.
The estimated listing price is calculated by adding the latest GMP to the upper end of the IPO price band.
₹988 + ₹320 = ₹1,308
Based on the latest GMP, Symbiotec Pharmalab shares could potentially list at around ₹1,308 per share.
The estimated gain is ₹320 per share, equivalent to a potential return of 32.39% over the IPO price.
With a lot size of 15 shares, an investor applying at the upper price band would pay ₹14,820. At the GMP-based estimated listing price of ₹1,308, the value of one lot would be approximately ₹19,620.
This implies an estimated profit of ₹4,800 per lot.
However, the actual listing price can differ from the GMP-based estimate.
Symbiotec Pharmalab IPO is a ₹1,757 crore book-built issue comprising a fresh issue and an offer for sale.
The fresh issue consists of 15.21 lakh shares aggregating to ₹150 crore, while the OFS comprises 1.63 crore shares worth ₹1,607 crore.
| IPO Particulars | Details |
|---|---|
| IPO Name | Symbiotec Pharmalab IPO |
| IPO Size | ₹1,757 crore |
| IPO Type | Book Building |
| IPO Dates | August 24–27, 2026 |
| Price Band | ₹938–₹988 |
| Lot Size | 15 Shares |
| Minimum Investment | ₹14,820 |
| Face Value | ₹2 per share |
| Fresh Issue | ₹150 crore |
| Offer for Sale | ₹1,607 crore |
| Listing | NSE and BSE |
| Allotment Date | August 28, 2026 |
| Refund Date | August 31, 2026 |
| Share Credit | August 31, 2026 |
| Tentative Listing Date | September 1, 2026 |
| Lead Manager | JM Financial Ltd. |
| Registrar | MUFG Intime India Pvt. Ltd. |
The public issue will open for subscription on August 24, 2026, and close on August 27, 2026.
The allotment is expected to be finalised on August 28. Refunds and credit of shares are scheduled for August 31, while the shares are expected to list on both the NSE and BSE on September 1, 2026.
| Event | Date |
|---|---|
| IPO Opens | August 24, 2026 |
| IPO Closes | August 27, 2026 |
| Allotment | August 28, 2026 |
| Refund | August 31, 2026 |
| Credit of Shares | August 31, 2026 |
| Listing | September 1, 2026 |
Incorporated in 2002, Symbiotec Pharmalab is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.
The company has more than three decades of industry experience and has evolved from a lab-scale steroidal hormone API manufacturer into an industrial-scale, backward-integrated manufacturing platform.
Symbiotec serves both domestic and international markets across regulated and emerging regions.
The company has approvals from regulatory bodies including the US FDA, EU-GMP and South Korea’s Ministry of Food and Drug Safety, among others.
As of June 30, 2025, Symbiotec operated two industrial-scale API manufacturing facilities, with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
The company highlights several competitive strengths, including:
Symbiotec Pharmalab has reported growth in revenue and profitability in FY2026.
The company’s total income increased from ₹755.98 crore in FY2025 to ₹872.26 crore in FY2026, representing growth of approximately 15%.
Profit after tax increased from ₹96.79 crore to ₹109.90 crore, up around 14% during the same period.
EBITDA increased from ₹206.11 crore in FY2025 to ₹231.97 crore in FY2026.
| Financial Year | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Assets | ₹1,294.79 Cr | ₹1,579.65 Cr | ₹1,780.79 Cr |
| Total Income | ₹723.33 Cr | ₹755.98 Cr | ₹872.26 Cr |
| Profit After Tax | ₹100.06 Cr | ₹96.79 Cr | ₹109.90 Cr |
| EBITDA | ₹177.04 Cr | ₹206.11 Cr | ₹231.97 Cr |
| Net Worth | ₹720.68 Cr | ₹821.15 Cr | ₹1,158.64 Cr |
| Total Borrowings | ₹247.21 Cr | ₹540.92 Cr | ₹387.91 Cr |
The company’s borrowings declined from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026.
For FY2026, Symbiotec Pharmalab reported a ROE of 11.19% and ROCE of 11.56%.
Its PAT margin stood at 12.60%, while the EBITDA margin was 26.59%.
| KPI | FY2026 | FY2025 |
|---|---|---|
| ROE | 11.19% | 12.66% |
| ROCE | 11.56% | 11.80% |
| RoNW | 9.48% | 11.79% |
| PAT Margin | 12.60% | 12.80% |
| EBITDA Margin | 26.59% | 27.26% |
| NAV | ₹184.69 | ₹150.17 |
| Price-to-Book | 5.35x | 6.58x |
At the upper IPO price of ₹988, the company is valued at a post-issue P/E multiple of 56.81x, compared with 55.44x on a pre-IPO basis.
The post-issue market capitalisation at the offer price is estimated at approximately ₹6,244.43 crore.
| Valuation Metric | Pre-IPO | Post-IPO |
|---|---|---|
| EPS | ₹17.82 | ₹17.39 |
| P/E | 55.44x | 56.81x |
| Market Cap at Offer Price | ₹6,094 Cr | ₹6,244.43 Cr |
The valuation makes the IPO’s pricing an important factor for investors to evaluate alongside the company’s growth prospects and pharmaceutical manufacturing capabilities.
A significant portion of the net IPO proceeds will be used towards reducing the company’s outstanding borrowings.
The company proposes to use ₹112.50 crore for the prepayment or repayment, fully or partially, of certain outstanding borrowings.
The remaining proceeds will be used for general corporate purposes.
The debt-reduction component could help strengthen the company’s balance sheet and potentially reduce its finance costs.
The sharp rise in the Symbiotec Pharmalab IPO GMP to ₹320 indicates strong grey market expectations ahead of the IPO opening.
The GMP-based estimated listing premium has increased from 22.27% on August 19 to 32.39% on August 21. The company’s revenue and PAT also grew in FY2026, while borrowings declined compared with FY2025.
However, the IPO is priced at a post-issue P/E of around 56.81x, making valuation an important consideration for investors.
GMP should therefore be considered alongside the company’s financial performance, valuation, competitive position, regulatory track record and growth prospects.
Disclaimer – The stock/s and indices mentioned in this article are discussed solely for informational and educational purposes. It should not be construed as investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult a financial advisor before making any investment decisions. Investments in securities markets are subject to market risks. Read all the related documents carefully before investing.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
